AZ's Imfinzi shows OS benefit in non-progressing Phase III NSCLC trial

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Imfinzi durvalumab significantly improved overall survival (OS) vs. placebo, meeting the second of two primary endpoints in the Phase III PACIFIC trial in 713 patients

Read the full 302 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE